Hyperaldosteronism: Clinical Manifestations and Treatment
For hyperaldosteronism, treat unilateral disease with laparoscopic adrenalectomy and bilateral disease with spironolactone (first-line) or eplerenone (if anti-androgenic side effects occur), targeting blood pressure normalization and reduction of cardiovascular mortality. 1
Clinical Manifestations
Cardiovascular and Metabolic Symptoms
Primary aldosteronism (PA) presents with hypertension as the cardinal feature, often resistant to standard therapy. The condition carries substantially higher cardiovascular risk than essential hypertension at equivalent blood pressure levels 1:
- Stroke risk increased 2.58-fold
- Coronary artery disease risk increased 1.77-fold
- Atrial fibrillation risk increased 3.52-fold
- Heart failure risk increased 2.05-fold
- Metabolic syndrome risk increased 1.53-fold
- Left ventricular hypertrophy risk increased 2.29-fold
Key Clinical Features
Hypokalemia is present in only 28% of patients and should not be relied upon as a primary indicator 2. When present, patients may experience:
- Muscle weakness, paresthesias, or tetany
- Renal dysfunction and nephrogenic diabetes insipidus
- In severe cases, paralysis 3
Critical Pitfall
The absence of hypokalemia does not exclude PA—most patients remain normokalemic, making the diagnosis easily missed if clinicians wait for low potassium levels before screening 1, 2.
Treatment Algorithm
Step 1: Determine Lateralization
The treatment pathway depends entirely on whether aldosterone excess is unilateral or bilateral, determined by adrenal vein sampling or functional imaging 1, 4.
Step 2A: Unilateral Disease (Surgically Curable)
Unilateral laparoscopic adrenalectomy is the gold standard for aldosterone-producing adenoma or unilateral hyperplasia 1, 5.
Pre-operative preparation (8-10 weeks):
- Initiate spironolactone 25-400 mg daily (usual dose 100-200 mg) to correct metabolic abnormalities and control blood pressure 6
- Normalize potassium levels
- Optimize blood pressure control
Expected outcomes:
- Nearly 100% of patients experience blood pressure improvement
- Approximately 50% achieve complete cure of hypertension 7
- Reduces cardiometabolic risk associated with aldosterone hypersecretion 1
Important caveat: Many patients remain hypertensive post-adrenalectomy and require continued antihypertensive therapy, though typically with fewer medications 6.
Step 2B: Bilateral Disease (Medical Management)
Spironolactone is the first-line mineralocorticoid receptor antagonist (MRA) 1, 4, 5:
- Starting dose: 25 mg daily
- Usual effective dose: 50-100 mg once daily 4
- Maximum dose: 300-400 mg daily if needed 1, 4
- Goal: Normalize blood pressure and maintain high-normal serum potassium without oral supplements 8
Eplerenone as second-line alternative 1:
- Requires 2-3 times higher doses than spironolactone
- Administered 2-3 times daily (less convenient)
- Major advantage: Does not cause gynaecomastia or erectile dysfunction in men 1, 4
- Use when anti-androgenic side effects of spironolactone are intolerable
Adjunctive therapy: Add thiazide diuretics, beta-blockers, or calcium channel blockers if blood pressure remains uncontrolled on MRA alone 6.
Newer agents under investigation (not yet standard of care): Non-steroidal MRAs (finerenone, exarenone) and aldosterone synthase inhibitor (baxdrostat) 4.
Step 2C: Special Case - Familial Hyperaldosteronism Type 1
For glucocorticoid-remediable aldosteronism (familial hyperaldosteronism type 1):
- First-line: Low-dose dexamethasone to suppress ACTH and normalize blood pressure 4, 5
- Add MRA if blood pressure fails to normalize with glucocorticoid alone 5
- Safe during pregnancy 4
Treatment Goals (PASO Criteria)
The Primary Aldosteronism Outcome (PASO) group criteria define treatment success 1:
- Normalize blood pressure to target levels
- Normalize excessive aldosterone production
- Improve associated comorbidities (cardiovascular disease, metabolic syndrome)
- Reduce mortality risk
Why Targeted Treatment Matters
Untreated PA causes disproportionate organ damage beyond blood pressure elevation alone 9:
- Arterial stiffness and cardiac remodeling
- Progressive renal dysfunction
- Accelerated cardiovascular events
Targeted treatment with MRAs or surgery demonstrably reduces these risks and improves cardiovascular and renal outcomes 10, 11. This is why screening and specific treatment are essential—generic antihypertensive therapy does not adequately address aldosterone-mediated damage 1.
Common Clinical Pitfalls
- Waiting for hypokalemia to screen - Most PA patients are normokalemic 2
- Assuming surgery cures all cases - 50% remain hypertensive and need ongoing treatment 7
- Using inadequate MRA doses - Titrate to effect, often requiring 100-200 mg spironolactone daily 6
- Not considering eplerenone early - Switch promptly if anti-androgenic effects occur rather than abandoning MRA therapy 1, 4